A clinical study on Efficacy of Ayurveda intervention on Stable coronary Artery Disease

Phase 3

• Conditions: Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

• Registration Number: CTRI/2024/02/062553
• Lead Sponsor: Central Council for Research in Ayurvedic Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Clinically diagnosed and confirmed cases of stable coronary artery disease such as already Angiographically documented one two or three vessel coronary disease

2. If not Confirmation of CAD may be done by any of the following Exercise stress testing or pharmacologic stress testing or an anatomic assessment of the coronary arteries or either with coronary computed tomography angiography (CTA) or an invasive coronary angiogram as and when required

3. Willing to be a part of the study

Exclusion Criteria

1. Patients having IHD with specific conditions like acute myocardial infarction unstable angina pectoris congenital anomalies valvular diseases hypertrophic cardiomyopathies and congestive cardiac failure

2. History of PTCA or CABG within 90 days

History of Renal dysfunction (Sr creatinine 1.2 mg%) chronic kidney disease GFR less than 60 ml per min

3. History of active liver disease

Patients with poorly controlled Hypertension more than 160 by 100 mm of Hg and Patients with poorly controlled Diabetes Mellitus HbA1c more than 8.0 percent

4. Active liver disease AST and ALT, total bilirubin, ALP more than 2 times upper normal limit

5. Pulmonary dysfunction COPD CVA Psychiatric illness malignancy etc.

6. Patients on prolonged more than 6 weeks medication with corticosteroids or antidepressants or anti-cholinergics etc or any other drugs that may have an influence on the outcome on the study

7. Participants who were tested COVID 19 positive through a positive RT PCR in the last 30 days

8. Participants with Post COVID 19 complications or BP fluctuations following disease

9. History of hypersensitivity towards the trial drug or any ingredient

10. History of substance abuse or alcohol intake

11. Pregnant or lactating women

12. Any other condition which the PI thinks may jeopardize the safety of the patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified